Lexeo Therapeutics (LXEO) Non Operating Income (2022 - 2026)

Lexeo Therapeutics has reported Non Operating Income for 5 years, with the latest figure at $2.1 million in Q1 2026.

• Quarterly Non Operating Income rose 85.99% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.3 million (up 47.48% YoY) and the FY2025 annual result came in at $9.3 million, up 25.06% from the prior year.
• Non Operating Income retreated to $2.1 million in Q1 2026 per LXEO's latest filing, from $2.2 million in the prior quarter.
• Over five years, Non Operating Income peaked at $4.6 million in Q2 2025 and troughed at $165000.0 in Q3 2023.
• A 5-year average of $1.5 million and a median of $1.4 million in 2025 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2023 and 2024: Non Operating Income plunged 61.36% in 2023, then jumped 1144.85% in 2024.
• Over 5 years, Non Operating Income stood at $620000.0 in 2022, then advanced by 26.94% to $787000.0 in 2023, then soared by 85.26% to $1.5 million in 2024, then soared by 50.69% to $2.2 million in 2025, then decreased by 2.73% to $2.1 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $2.1 million, $2.2 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.